---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-010123"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2024-02-02T23:59:59+00:00"
generated_at: "2026-06-06T09:47:42.409055+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cara Therapeutics receives Nasdaq non-compliance notice for bid price below $1.00 per share

## Summary
- Nasdaq notified Cara on Feb 1, 2024 that its common stock bid price was below $1.00 for 30 consecutive business days.
- Company has 180 calendar days, until July 30, 2024, to regain compliance by closing at $1.00+ for 10 consecutive days.
- If not compliant by July 30, Cara may transfer to Nasdaq Capital Market for an additional 180-day cure period.
- Failure to regain compliance could result in delisting from The Nasdaq Global Select Market.
- Cara intends to monitor its stock price and consider available options, but no assurance of regaining compliance.

## SEC filing metadata
- accession: 0001104659-24-010123
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2024-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465924010123/0001104659-24-010123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465924010123/tm245054d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-010123
- JSON: https://secwatch.observer/filing/0001104659-24-010123.json
- Plain text: https://secwatch.observer/filing/0001104659-24-010123.txt

## Key facts
- Listing & Compliance Notices
  Tvardi Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: February 1, 2024, Cara Therapeutics, Inc. (the “ Company ”) received a notice from The Nasdaq Stock Market (“ Nasdaq ”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market. The Company has 180 calendar days, or until July 30, 2024, to regain compliance with the minimum bid price requirement. To regain com
  evidence_url: https://www.sec.gov/Archives/edgar/data/1346830/000110465924010123/0001104659-24-010123-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.